Ribatti D, Vacca A
Department of Human Anatomy and Histology, University of Bari Medical School, Policlinico, Bari, Italy.
Leukemia. 2005 Sep;19(9):1525-31. doi: 10.1038/sj.leu.2403852.
Very few drugs had a history similar to that of thalidomide (alpha-N-[phthalimido] gluramide). First introduced in the late 1950s in Germany, in 1961 thalidomide was withdrawn due to its teratogenic effects. More than three decades after, it is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. The discovery that thalidomide inhibits angiogenesis led to preclinical and clinical trials as an anticancer agent in the treatment of solid tumours and haematological malignancies, as summarized in this review article. More recently, structural analogues of thalidomide have been synthesized in order to explore potential molecular targets of thalidomide, as well as to identify new agents with improved therapeutic efficacy.
很少有药物的历史能与沙利度胺（α-N-邻苯二甲酰亚氨基戊二酰胺）相媲美。20世纪50年代末沙利度胺首次在德国推出，1961年因其致畸作用而被撤回。三十多年后，由于其具有免疫调节和抗炎特性，它正吸引着越来越多的关注。沙利度胺具有抑制血管生成的作用，这一发现促使其作为抗癌药物用于实体瘤和血液系统恶性肿瘤治疗的临床前和临床试验，本文对此进行了综述。最近，沙利度胺的结构类似物已被合成，以探索沙利度胺的潜在分子靶点，并确定具有更高治疗效果的新药物。
